• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

    5/1/25 9:16:04 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LXEO alert in real time by email

    NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its AAV manufacturing approach will be presented at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 13-17, 2025 in New Orleans, LA.

    "The data being presented at ASGCT underscore the strength of our industry-leading capabilities in AAV manufacturing with high yield and high quality," said José Manuel Otero, Chief Technical Officer of Lexeo Therapeutics. "Scientists at Lexeo have optimized a manufacturing platform that can maintain purity and potency while significantly improving scalability of production and reducing cost. Ultimately this platform will enable Lexeo to deliver more efficiently against key milestones in our clinical-stage gene therapy programs and will help to accelerate our mission to bring potentially transformative therapies to patients as quickly as possible."

    Presentation Details:

    Title: Improving VP1 Ratios Impact on CQAs in rh10 AAV Manufactured through Sf9 Platform

    Presenter: Elena Bianchetti, Lexeo Therapeutics

    Date/Time: Tuesday, May 13, 6:00 – 7:30 p.m. CST

    Session Title: Tuesday Poster Reception

    Abstract Number: 948

    Title: Development of a Novel High-Yielding Scalable Sf9-Baculovirus Platform to Produce Quality AAV at 200L Scale

    Presenter: Eric Lin, Lexeo Therapeutics

    Date/Time: Thursday, May 15, 5:30 – 7:00 p.m. CST

    Session Title: Thursday Poster Reception

    Abstract Number: 1972

    About Lexeo Therapeutics

    Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, LX2020 for the treatment of plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

    Cautionary Note Regarding Forward-Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Lexeo's expectations and plans regarding its current product candidates and programs, and the timing and likelihood of potential regulatory approval. Words such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo's filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company's control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: risks and uncertainties related to global macroeconomic conditions and related volatility; expectations regarding the initiation, progress, and expected results of Lexeo's preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo's Annual Report on Form 10-K for the annual period ended December 31, 2024, filed with the SEC on March 24, 2025 and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

    Media Response:

    [email protected]



    Primary Logo

    Get the next $LXEO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LXEO

    DatePrice TargetRatingAnalyst
    7/31/2025$20.00Outperform
    Oppenheimer
    6/13/2024$28.00Outperform
    Robert W. Baird
    6/6/2024$22.00Buy
    H.C. Wainwright
    11/28/2023$20.00Overweight
    JP Morgan
    11/28/2023$20.00Buy
    Stifel
    11/28/2023$19.00Outperform
    Leerink Partners
    11/28/2023$22.00Outperform
    RBC Capital Mkts
    11/28/2023$23.00Buy
    Chardan Capital Markets
    More analyst ratings

    $LXEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Lexeo Therapeutics with a new price target

    Oppenheimer initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $20.00

    7/31/25 7:37:07 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Robert W. Baird initiated coverage on Lexeo Therapeutics with a new price target

    Robert W. Baird initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $28.00

    6/13/24 7:10:25 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Lexeo Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $22.00

    6/6/24 7:17:54 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    SEC Filings

    View All

    Lexeo Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)

    10/7/25 6:03:59 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.

    SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    8/14/25 4:58:22 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.

    SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    8/14/25 1:40:44 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Townsend Richard Nolan was granted 2,193 shares, increasing direct ownership by 1.00% to 222,251 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    9/16/25 5:30:06 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Chief Executive Officer Townsend Richard Nolan sold $5,205 worth of shares (1,115 units at $4.67), decreasing direct ownership by 0.50% to 220,058 units (SEC Form 4)

    4/A - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    9/10/25 4:59:33 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Tamayo Louis Edward was granted 45,000 shares (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    9/3/25 2:00:05 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- Ohio State researchers recently solved a critical mystery explaining why some cancer immunotherapies fail[1], while a University of Chicago team discovered a common supplement that supercharges immune cells against tumors[2]. These breakthroughs are propelling the global cancer treatment market from $282 billion in 2025 toward $643.5 billion by 2034[3], creating powerful momentum for companies pioneering next-generation approaches including GT Biopharma, Inc. (NASDAQ:GTBP), Lexeo Therapeutics, Inc. (NASDAQ:LXEO), Anixa Biosciences, Inc. (NASDAQ:ANIX), Tempus AI, Inc. (NASDAQ:TEM)

    10/8/25 10:58:00 AM ET
    $ANIX
    $CTOR
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Computer Software: Programming Data Processing

    Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

    U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Interim clinical data show sustained or deepening improvements in the majority of participants across both cardiac and neurologic measures of Friedreich ataxia Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 18% mean reduction in LVMI at 6 months and 23% mean reduction at 12 months, exceeding FDA-aligned target threshold of 10% reduction Clinically meaningful improvement observed in the modified Friedreich Ataxia Rating Scale (mFARS), indicative of slowed disease

    10/7/25 6:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

    Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia LX2006 selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access Eight participants dosed in Phase I/II clinical trial (HEROIC-PKP2) of LX2020 for PKP2-ACM; interim clinical data update on track for second half of 2025 Strategic partnership announced with Perceptive Xontogeny Venture Funds and venBio Partners to advance non-viral, RNA-based therapeutics for gene

    8/14/25 7:30:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cholmondeley Paula H bought $104,852 worth of shares (15,000 units at $6.99), increasing direct ownership by 96% to 30,627 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    11/26/24 5:00:06 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Leadership Updates

    Live Leadership Updates

    View All

    Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

    NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs. "Kyle has an exceptional track record as an operator and life sciences portfolio manager, and we are excited to welcome him to Lexeo at a time when we are advancing our pipeline and tran

    12/19/24 7:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

    Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/

    11/13/24 7:30:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

    Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; data update from Cohort 1 on track for 2H 2024 Cash and cash equivalents of $175.0 million expected to provide operational runway into 2027 NEW YORK, Aug. 12, 2024 (GLOBE N

    8/12/24 7:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Financials

    Live finance-specific insights

    View All

    Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

    Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of participants LX1001 well tolerated across all dose cohorts with no reports of amyloid-related imaging abnormalities (ARIA) Company to host webcast today at 7:00 AM ET NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced positive interim results from the Phase 1/2 study of LX1001

    10/30/24 6:14:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

    NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo's ongoing SUNRISE-FA Phase 1/2 clinical

    7/11/24 8:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/14/24 5:49:30 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/14/24 4:45:58 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/14/24 12:32:15 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care